Revance Therapeutics Inc. has never made a secret of its goal to build a better Botox. The Newark, Calif.-based company is making swift progress to reach that target as it prepares to file a BLA for lead program RT-002, an injectable formulation of daxibotulinumtoxinA, in moderate to severe glabellar lines after moving RT-002 into a pivotal phase III to treat cervical dystonia.